Sinocelltech(SH:688520) Xin Lang Zheng Quan·2025-09-08 03:31Company Overview - Shenzhou Cell is located in Beijing Economic and Technological Development Zone and was established on April 23, 2007. The company went public on June 22, 2020. Its main business involves the research and industrialization of biopharmaceutical products for malignant tumors, autoimmune diseases, infectious diseases, and genetic diseases [1][2]. Stock Performance - As of September 8, Shenzhou Cell's stock price was 61.74 CNY per share, with a market capitalization of 27.495 billion CNY. The stock has increased by 70.41% year-to-date but has seen a decline of 6.27% over the last five trading days and 5.65% over the last twenty days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent occurrence on July 4, where it recorded a net buy of 87.5322 million CNY [1]. Financial Performance - For the first half of 2025, Shenzhou Cell reported a revenue of 972 million CNY, a decrease of 25.50% year-on-year. The net profit attributable to the parent company was -33.7711 million CNY, reflecting a significant decline of 126.87% year-on-year [2]. Shareholder Information - As of June 30, 2025, the number of shareholders was 9,754, a decrease of 12.74% from the previous period. The average number of circulating shares per person increased by 14.60% to 45,656 shares [2]. - Notable changes in institutional holdings include the entry of new shareholders such as Southern CSI 500 ETF and China Europe Medical Health Mixed A, while Hong Kong Central Clearing Limited and China Merchants National Bio-Medical Index A exited the top ten circulating shareholders [2]. Industry Classification - Shenzhou Cell belongs to the pharmaceutical and biotechnology sector, specifically in the subcategory of biopharmaceuticals, with a focus on innovative drugs, vaccines, biomedicine, anti-cancer drugs, and cell therapy [2].